In the past week, RCKT stock has gone down by -24.40%, with a monthly decline of -30.16% and a quarterly plunge of -45.09%. The volatility ratio for the week is 6.11%, and the volatility levels for the last 30 days are 6.03% for Rocket Pharmaceuticals Inc The simple moving average for the last 20 days is -21.21% for RCKT’s stock, with a simple moving average of -57.85% for the last 200 days.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
Moreover, the 36-month beta value for RCKT is 0.95. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RCKT is 98.97M and currently, short sellers hold a 11.16% of that float. On March 31, 2025, RCKT’s average trading volume was 1.51M shares.
RCKT) stock’s latest price update
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has experienced a decline in its stock price by -13.04 compared to its previous closing price of 7.59. However, the company has seen a fall of -24.40% in its stock price over the last five trading days. zacks.com reported 2025-02-28 that RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with BMO Capital Markets repeating the rating for RCKT by listing it as a “Outperform.” The predicted price for RCKT in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $32. The rating they have provided for RCKT stocks is “Outperform” according to the report published on December 30th, 2024.
Jefferies gave a rating of “Buy” to RCKT, setting the target price at $29 in the report published on December 18th of the previous year.
RCKT Trading at -30.87% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.55% of loss for the given period.
Volatility was left at 6.03%, however, over the last 30 days, the volatility rate increased by 6.11%, as shares sank -25.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.75% lower at present.
During the last 5 trading sessions, RCKT fell by -24.86%, which changed the moving average for the period of 200-days by -71.37% in comparison to the 20-day moving average, which settled at $8.38. In addition, Rocket Pharmaceuticals Inc saw -47.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Schwartz Jonathan David, who sale 6,532 shares at the price of $10.58 back on Feb 25 ’25. After this action, Schwartz Jonathan David now owns 237,638 shares of Rocket Pharmaceuticals Inc, valued at $69,109 using the latest closing price.
Schwartz Jonathan David, the of Rocket Pharmaceuticals Inc, sale 2,754 shares at $23.35 during a trade that took place back on May 17 ’24, which means that Schwartz Jonathan David is holding 169,659 shares at $64,306 based on the most recent closing price.
Stock Fundamentals for RCKT
The total capital return value is set at -0.56. Equity return is now at value -54.14, with -47.30 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -144.86.
Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
To wrap up, the performance of Rocket Pharmaceuticals Inc (RCKT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
